One of the most stubborn obstacles to curing HIV is not the virus itself in active circulation, but the silent reservoir it establishes inside CD4+ T cells — cells that persist indefinitely even as antiretroviral therapy suppresses viral replication to undetectable levels. Understanding which cells harbor intact provirus, and what immunological identity those cells carry, has long been a technical bottleneck. A new platform may now crack that open.
Researchers published in PNAS developed an open-source single-cell sequencing approach called DAb-seq, which simultaneously profiles proviral DNA sequences and surface protein markers (epitopes) on individual CD4+ T cells from people on antiretroviral therapy. This dual-resolution method allows investigators to link the genetic integrity and integration site of latent HIV provirus directly to the immunophenotype of the cell harboring it — identifying, for instance, whether intact versus defective proviruses preferentially reside in memory, effector, or regulatory T-cell subsets. The platform's open-source design also means the methodology is available for broader scientific adoption without proprietary barriers.
This work sits at the intersection of two previously siloed research domains: HIV reservoir virology and T-cell immunology. Earlier approaches could characterize proviral sequences or cell surface markers, but rarely both simultaneously at single-cell resolution. The ability to co-map these features addresses a fundamental question: are certain CD4+ T-cell subsets acting as privileged sanctuaries for replication-competent virus, and if so, why? From a longevity and immune health standpoint, chronic HIV infection — even when well-controlled — is associated with accelerated immunosenescence, persistent inflammation, and elevated risk of non-AIDS comorbidities. Tools that dissect reservoir composition may eventually guide cure strategies targeting specific cellular niches. Limitations worth noting: this is a platform development and characterization study; its clinical translation and the size of the patient cohort require closer inspection of the full paper. Whether DAb-seq findings replicate across diverse ART-suppressed populations remains to be established.